Trump's New Cabinet May Foster Biopharmaceutical Prosperity

As President Donald J. Trump gradually assembles his cabinet, the appointments of new officials may signal a positive trend for the biopharmaceutical industry over the next four years.

On Tuesday, President Trump nominated Andrew Ferguson to be the chair of the Federal Trade Commission (FTC). According to Reuters, Ferguson is one of the two FTC commissioners confirmed by the Senate during President Biden's administration.

At the same time, Trump announced on the social platform Truth Social that he plans to nominate Mark Meador, a partner at Kressin Meador Powers law firm, to be an FTC commissioner. If Meador is confirmed, he will replace the current FTC chair, Lina Khan, whose term at the antitrust agency has expired.

The New York Times pointed out that the current FTC chair, Khan, has become a "political lightning rod" for challenging major mergers. Under Khan's leadership, the FTC has taken several notable actions that have caused dissatisfaction within the pharmaceutical industry.

Notably, in 2021, the FTC announced that it would collaborate with the Department of Justice, state attorneys general, and competition agencies from other countries to review the market impact of significant biopharmaceutical mergers. The process was initiated by then-acting chair Rebecca Kelly Slaughter, and Khan continued to advance it during her tenure.

In a September 2023 statement, FTC commissioners Khan, Slaughter, and Alvaro Bedoya detailed their reasons for blocking Amgen's $27.8 billion acquisition of Horizon. They argued that the deal could weaken competition in the market for FDA-approved treatments for rare diseases such as thyroid eye disease and chronic refractory gout, leading to a monopoly on Horizon's Tepezza and Krystexxa drugs. Although Amgen ultimately prevailed and completed the transaction, the FTC's stance indicates a rigorous review of mergers in the biopharmaceutical sector.

Additionally, the FTC under Khan has launched a broad crackdown on patents improperly listed in the FDA's Orange Book, which catalogs brand drug patents for reference by generic drug developers.

Under Khan's leadership, the FTC also approved the use of a controversial provision known as "march-in rights," which ostensibly allows the government to take over patents developed with federal funding to support competition in the biopharmaceutical field.

In contrast, according to The New York Times on Tuesday, Ferguson indicated in discussions with Trump's transition team that the FTC should continue to review the market positions of large tech platforms, but he has pushed back on some of Khan's agenda.

The Biosecure Act MIA, part of the U.S. Defense Authorization Act, represents a significant victory for Chinese biopharmaceutical service providers.

The Associated Press largely echoed Ferguson's viewpoint, suggesting that his nomination is a positive sign for transactions in the coming years, indicating that the agency may adopt a "lax policy" in antitrust enforcement.

The AP quoted Anthony DiResta, a consumer protection attorney at Holland & Knight, in a recent analysis report stating, "These changes could make the FTC more favorable to businesses than in recent years, although the specific extent remains to be determined."

Ferguson himself wrote on X that he plans to "end the hatred of competition and free speech by large tech companies" while ensuring that "America is the world's technology leader and the best place for innovators to bring new ideas to life."

Overall, Ferguson's appointment and his attention to antitrust issues concerning large tech companies in healthcare may be a welcome sign for the biopharmaceutical industry. In recent years, the biopharmaceutical sector has faced strict scrutiny over mergers, resulting in a significant decline in the total value of signed transactions in 2024.